Necitumumab
Based on 1 Customer Validation
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.90%
- CAS 番号: 906805-06-9
- 分子量:144.78 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
EGFR アイソフォーム固有の製品をすべて表示
More
生物活性
Human IgG1 kappa
Human
ERBB1/EGFR/HER1
Necitumumab specifically binds to the EGF binding site of human EGFR with high affinity (dissociation constant 0.32 nM) and blocks ligand binding with an IC50 of 1-2 nM[1].
Necitumumab neutralizes ligand-induced EGFR phosphorylation with an IC50 of 1.5-3 nM[1].
Necitumumab inhibits the proliferation of EGFR-dependent colorectal tumour cells with an IC50 of 0.8-1.0 nM[1].
Necitumumab induces EGFR internalization and degradation, and triggers antibody-dependent cellular cytotoxicity in EGFR-expressing human cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic mice with A549 and NCI-H1650 xenograft (5-6 week; female)[2]
-
Dosage:60 mg/kg
-
Administration:I.p.; twice a week for 2 weeks
-
Result:Reduced tumor volume.
Increased Ki-67-positive.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human ERBB1/EGFR/HER1, His Tag can bind Necitumumab. The EC50 for this effect is 11.47 ng/mL. -
Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Necitumumab (anti-ERBB1/EGFR/HER1) (HY-P9964). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 906805-06-9
-
性状 Liquid
-
分子量 144.78 kDa
-
Color Colorless to light yellow
-
SMILES
[Necitumumab]
-
別名
11F8; IMC-11F8; LY3012211
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Garnock-Jones KP, et al. Necitumumab: First Global Approval. Drugs. 2016;76(2):283-289. [Content Brief]
[2]. Samakoglu S, et al. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Necitumumab 関連分類
HY-P9964 関連分類
Powered by Bioz